On Wednesday, Bharat Biotech said that it has successfully air-shipped its COVID-19 vaccine Covaxin to 11 cities in India in the early hours and that it has donated 16.5 lakh doses to the center.
The company also expressed its deepest gratitude to the nation, all clinical trial volunteers, and its partners for making this a successful and milestone public-private partnership for the development of India’s first COVID-19 vaccine, a press release said.
After having received the government purchase order for 55 lakh doses, Bharat Biotech shipped the first batch of vaccines (each vial containing 20 doses) to Gannavaram (Vijayawada), Guwahati, Patna, Delhi, Kurukshetra, Bangalore, Pune, Bhubaneswar, Jaipur, Chennai and Lucknow.
Covaxin is a highly purified and inactivated two-dose SARS-CoV-2 vaccine, manufactured in a Vero cell manufacturing platform with an excellent safety track record of more than 300 million doses, the release said.
It is India’s totally indigenous COVID-19 vaccine, developed in collaboration with the Indian Council of Medical Research and National Institute of Virology.
The inactivated vaccine is developed and manufactured in Bharat Biotech’s BSL-3 (Bio-Safety Level 3) biocontainment facility, one of its kind in the world.
